Correction - Holding(s) in Company

Summary by AI ^BETAClose X

PureTech Health plc has announced a correction regarding a TR-1 notification of major holdings previously issued by Citigroup Inc. Shareholders are instructed to disregard the notification announced on May 7, 2026, as it was submitted in error. Instead, they should refer to the TR-1 notification concerning Citigroup Inc. that was announced on April 27, 2026.

Disclaimer*

PureTech Health PLC

15 May 2026

15 May 2026

PureTech Health plc

Correction - TR-1 Notification of Major Holdings

On 14 May 2026, PureTech Health plc ("PureTech" or the "Company"), was notified by Citigroup Inc. that the TR-1 notification it submitted to the Company on 7 May 2026, and which was subsequently announced by the Company on 7 May 2026 under RNS number 5007D, was provided in error.

Accordingly, shareholders should disregard the TR-1 notification announced by the Company on 7 May 2026 and instead refer to the TR-1 notification in relation to Citigroup Inc. announced by the Company on 27 April 2026, which is available under RNS number 1025C.

About PureTech Health

PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders.

For more information, visit www.puretechhealth.com or connect with us on LinkedIn and X (formerly Twitter) @puretechh.

Contact:
Investor Relations
IR@puretechhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END